Encompass Health reports results for second quarter 2021

  • Oops!
    Something went wrong.
    Please try again later.
·12 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Increases full-year guidance for 2021

BIRMINGHAM, Ala., July 27, 2021 /PRNewswire/ -- Encompass Health Corporation (NYSE: EHC), a national leader in integrated healthcare, offering facility-based and home-based patient care through its network of inpatient rehabilitation hospitals and home health and hospice agencies, today reported its results of operations for the second quarter ended June 30, 2021.

(PRNewsfoto/Encompass Health Corporation)
(PRNewsfoto/Encompass Health Corporation)

"Business momentum accelerated in the second quarter of 2021 and resulted in strong revenue and earnings growth in both segments over the same period of 2020 and 2019," said President and Chief Executive Officer of Encompass Health Mark Tarr. "As a result of our strong operating trends and year-to-date performance, we are again raising our full-year 2021 guidance."

Consolidated results






Growth


Q2 2021


Q2 2020


Dollars


Percent


(In Millions, Except Per Share Data)

Net operating revenues

$

1,287.7



$

1,074.1



$

213.6



19.9

%

Income from continuing operations attributable to Encompass Health per diluted share

1.13



0.34



0.79



232.4

%

Adjusted earnings per share

1.17



0.31



0.86



277.4

%

Cash flows provided by operating activities

255.9



222.3



33.6



15.1

%

Adjusted EBITDA

278.9



162.2



116.7



71.9

%

Adjusted free cash flow

205.6



168.2



37.4



22.2

%


Six Months Ended June 30,






2021


2020





Cash flows provided by operating activities

$

414.4



$

251.6



$

162.8



64.7

%

Adjusted free cash flow

313.0



242.8



70.2



28.9

%

Revenue growth resulted from increased volumes and favorable pricing.

The increase in income from continuing operations attributable to Encompass Health per diluted share and adjusted earnings per share in 2021 primarily resulted from revenue growth.

The increase in year-to-date cash flows provided by operating activities and adjusted free cash flow primarily resulted from revenue growth and the timing of maintenance capital expenditures in 2021.

See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.

Inpatient rehabilitation segment results






Growth


Q2 2021


Q2 2020


Dollars


Percent

Net operating revenues:

(In Millions)

Inpatient

$

976.9



$

808.0



$

168.9



20.9

%

Outpatient and other

24.7



16.5



8.2



49.7

%

Total segment revenue

$

1,001.6



$

824.5



$

177.1



21.5

%










(Actual Amounts)

Discharges

49,492



41,682



7,810



18.7

%

Same-store discharge growth







16.9

%

Net patient revenue per discharge

$

19,739



$

19,385



$

354



1.8

%

Revenue reserves related to bad debt as a percent of revenue

1.7

%


1.4

%




30 basis points











(In Millions)

Adjusted EBITDA

$

254.0



$

180.3



$

73.7



40.9

%

  • Revenue - Inpatient revenue growth resulted from increased volumes and favorable pricing. Total discharge growth for the second quarter of 2021 was 18.7% with same-store growth of 16.9%. Same-store discharge growth in the second quarter of 2021 compared to the second quarter of 2019 was 1.6%.

    Growth in net patient revenue per discharge primarily resulted from an increase in reimbursement rates, the suspension of sequestration, improvement in discharge destination and prior period cost report adjustments partially offset by the timing of discharges between quarters.

    The increase in outpatient and other revenue included an increase of approximately $7 million in provider tax revenues (offset by $2.5 million of provider tax expenses included in other operating expenses).

  • Adjusted EBITDA - The 40.9% increase in Adjusted EBITDA in the second quarter of 2021 primarily resulted from revenue growth and effective productivity management. Adjusted EBITDA in the second quarter of 2020 included approximately $29 million of additional paid-time-off awarded to employees.

Home health and hospice segment results






Growth


Q2 2021


Q2 2020


Dollars


Percent

Net operating revenues:

(In Millions)

Home health revenue

$

232.3



$

201.8



$

30.5



15.1

%

Hospice revenue

53.8



47.8



6.0



12.6

%

Total segment revenue

$

286.1



$

249.6



$

36.5



14.6

%









Adjusted EBITDA

$

61.7



$

15.0



$

46.7



311.3

%









Home Health

Starts of care:

(Actual Amounts)

Episodic admissions

39,657



34,841



4,816



13.8

%

Same-store episodic admissions growth







12.9

%

Episodic recertifications

28,296



28,328



(32)



(0.1)

%

Total episodic starts of care

67,953



63,169



4,784



7.6

%









Total admissions

50,598



44,124



6,474



14.7

%

Same-store total admissions growth







13.8

%

Total recertifications

33,794



31,952



1,842



5.8

%

Total starts of care

84,392



76,076



8,316



10.9

%

Revenue per episode

$

2,968



$

2,920



$

48



1.6

%









Hospice

Admissions:








Same store

3,130



3,190



(60)



(1.9)

%

New store

168





168



5.3

%

Total admissions

3,298



3,190



108



3.4

%

  • Revenue - Total starts of care were up 10.9%. Total admissions increased 14.7%, including same-store admissions growth of 13.8%. Volume growth was achieved in spite of continued lower occupancy at skilled nursing and senior living facilities, as well as staffing challenges in certain markets. Elective procedures have returned to historic levels.

    The increase in revenue per episode resulted from an increase in reimbursement rates, as the timing of completed episodes offset the benefit of the suspension of sequestration.

    Growth in hospice admissions resulted from the acquisition of assets from Frontier Home Health and Hospice in June 2021.

  • Adjusted EBITDA - The 311.3% increase in Adjusted EBITDA in the second quarter of 2021 primarily resulted from lower cost per visit supported by the clinician compensation model changes implemented in May 2020, as well as effective management of overall productivity of full-time staff. Adjusted EBITDA in the second quarter of 2020 included approximately $14 million of additional paid-time-off awarded to employees.

General and administrative expenses


Q2 2021


% of
Consolidated
Revenue


Q2 2020


% of
Consolidated
Revenue


(In Millions)

General and administrative expenses, excluding stock-based compensation

$

36.8



2.9%


$

33.1



3.1%













General and administrative expenses decreased as a percent of consolidated revenue due to the increased revenue base year over year.

General and administrative expenses in the above table exclude $4.1 million in costs associated with the strategic alternatives review of the Company's home health and hospice business and $1.3 million of transaction costs associated with the Frontier acquisition for the second quarter of 2021.

2021 guidance

The Company increased its full-year guidance to reflect its second quarter results and strong operating trends.


Full-Year 2021 Guidance Ranges


Previous Guidance


Updated Guidance


(In Millions, Except Per Share Data)

Net operating revenues

$5,060 to $5,230


$5,100 to $5,250

Adjusted EBITDA

$1,000 to $1,030


$1,050 to $1,070

Adjusted earnings per share from continuing operations attributable to Encompass Health

$3.94 to $4.16


$4.32 to $4.47

On December 9, 2020, the Company announced it is exploring strategic alternatives for its home health and hospice business. The review is ongoing. Accordingly, the Company's 2021 guidance assumes the continuation of the current structure of the business for 2021. The guidance may change if a transaction occurs before the end of the year.

For additional considerations regarding the Company's 2021 guidance ranges, see the supplemental information posted on the Company's website at http://investor.encompasshealth.com. See also the "Other Information" section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.

Update on Strategic Alternatives Review for Home Health and Hospice Business

Encompass Health continues to explore strategic alternatives for its home health and hospice business. Based on the analysis to date, the Company's Board of Directors believes a full or partial separation of the home health and hospice business will enhance the long-term success and value of the business. The Company is pursuing a separation transaction by either public or private means.

Many of the key preparatory actions for a separation have been completed, including but not limited to, audited carve-out financial statements for the home health and hospice business, a confidential submission of a draft registration statement on Form S-1 with the United States Securities and Exchange Commission and certain required regulatory filings. While no assurance can be provided, the Company expects to announce a transaction in the second half of 2021.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of that jurisdiction.

Earnings conference call and webcast

The Company will host an investor conference call at 10:00 a.m. Eastern Time on Wednesday, July 28, 2021 to discuss its results for the second quarter of 2021. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.

The conference call may be accessed by dialing 877 587-6761 and giving the pass code 7294490. International callers should dial 706 679-1635 and give the same pass code. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.

About Encompass Health

As a national leader in integrated healthcare services, Encompass Health (NYSE: EHC) offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. With a national footprint that includes 140 hospitals and 249 home health locations and 94 hospice locations in 42 states and Puerto Rico, the Company provides high-quality, cost-effective integrated healthcare. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Other information

The information in this press release is summarized and should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the "June 2021 Form 10-Q"), when filed, as well as the Company's Current Report on Form 8-K filed on July 27, 2021 (the "Q2 Earnings Form 8-K"), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its July 28, 2021 earnings call.

The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company's adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q2 Earnings Form 8-K. Readers are encouraged to review the "Note Regarding Presentation of Non-GAAP Financial Measures" included in the Q2 Earnings Form 8-K which provides further explanation and disclosure regarding the Company's use of these non-GAAP financial measures.

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP.

However, the following reasonably estimable GAAP measures for 2021 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:

  • Interest expense and amortization of debt discounts and fees - estimate of $164 million to $174 million

  • Amortization of debt-related items - approximately $9 million

The Q2 Earnings Form 8-K and, when filed, the June 2021 Form 10-Q can be found on the Company's website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)



Three Months Ended
June 30,


Six Months Ended
June 30,


2021


2020


2021


2020


(In Millions, Except Per Share Data)

Net operating revenues

$

1,287.7



$

1,074.1



$

2,518.1



$

2,256.1


Operating expenses:








Salaries and benefits

708.2



651.9



1,395.4



1,331.0


Other operating expenses

172.7



148.3



335.0



307.9


Occupancy costs

20.2



20.3



40.4



40.5


Supplies

50.0



50.6



101.9



96.3


General and administrative expenses

54.2



43.0



92.8



78.6


Depreciation and amortization

63.4



60.7



125.9



119.5


Government, class action, and related settlements







2.8


Total operating expenses

1,068.7



974.8



2,091.4



1,976.6


Loss on early extinguishment of debt

1.0





1.0




Interest expense and amortization of debt discounts and fees

41.8



45.8



84.6



89.0


Other income

(4.6)



(5.8)



(6.0)



(3.9)


Equity in net income of nonconsolidated affiliates

(1.0)



(0.7)



(2.0)



(1.5)


Income from continuing operations before income tax expense

181.8



60.0



349.1



195.9


Provision for income tax expense

39.5



11.8



74.0



38.9


Income from continuing operations

142.3



48.2



275.1



157.0


(Loss) income from discontinued operations, net of tax

(0.3)



0.1



(0.3)




Net and comprehensive income

142.0



48.3



274.8



157.0


Less: Net and comprehensive income attributable to noncontrolling interests

(28.7)



(14.8)



(54.2)



(36.5)


Net and comprehensive income attributable to Encompass Health

$

113.3



$

33.5



$

220.6



$

120.5










Weighted average common shares outstanding:








Basic

99.0



98.7



99.0



98.5


Diluted

100.2



99.9



100.2



99.6


Earnings per common share:








Basic earnings per share attributable to Encompass Health common shareholders:








Continuing operations

$

1.14



$

0.34



$

2.22



$

1.22


Discontinued operations








Net income

$

1.14



$

0.34



$

2.22



$

1.22


Diluted earnings per share attributable to Encompass Health common shareholders:








Continuing operations

$

1.13



$

0.34



$

2.20



$

1.21


Discontinued operations








Net income

$

1.13



$

0.34



$

2.20



$

1.21


...







Amounts attributable to Encompass Health common shareholders:








Income from continuing operations

$

113.6



$

33.4



$

220.9



$

120.5


(Loss) income from discontinued operations, net of tax

(0.3)



0.1



(0.3)




Net income attributable to Encompass Health

$

113.3



$

33.5



$

220.6



$

120.5


Encompass Health Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)



June 30,
2021


December 31,
2020


(In Millions)

Assets




Current assets:




Cash and cash equivalents

$

73.2



$

224.0


Restricted cash

65.0



65.4


Accounts receivable

627.5



572.8


Other current assets

93.6



86.4


Total current assets

859.3



948.6


Property and equipment, net

2,391.2



2,206.6


Operating lease right-of-use assets

244.9



245.7


Goodwill

2,412.3



2,318.7


Intangible assets, net

435.5



431.3


Other long-term assets

269.7



295.0


Total assets

$

6,612.9



$

6,445.9


Liabilities and Shareholders' Equity




Current liabilities:




Current portion of long-term debt

$

66.8



$

38.3


Current operating lease liabilities

42.0



44.8


Accounts payable

145.1



115.0


Accrued expenses and other current liabilities

550.6



519.2


Total current liabilities

804.5



717.3


Long-term debt, net of current portion

3,105.7



3,250.6


Long-term operating lease liabilities

212.9



209.6


Deferred income tax liabilities

61.7



51.8


Other long-term liabilities

219.1



215.0



4,403.9



4,444.3


Commitments and contingencies




Redeemable noncontrolling interests

32.9



31.6


Shareholders' equity:




Encompass Health shareholders' equity

1,762.0



1,588.0


Noncontrolling interests

414.1



382.0


Total shareholders' equity

2,176.1



1,970.0


Total liabilities and shareholders' equity

$

6,612.9



$

6,445.9


Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)



Six Months Ended June 30,


2021


2020


(In Millions)

Cash flows from operating activities:




Net income

$

274.8



$

157.0


Loss from discontinued operations, net of tax

0.3




Adjustments to reconcile net income to net cash provided by operating activities—




Depreciation and amortization

125.9



119.5


Stock-based compensation

14.8



17.0


Deferred tax expense (benefit)

6.2



(9.1)


Other, net

4.0



7.8


Changes in assets and liabilities, net of acquisitions—




Accounts receivable

(38.1)



(38.5)


Other assets

(17.2)



20.0


Accounts payable

6.6



(0.4)


Accrued payroll

27.4



58.4


Other liabilities

10.3



(80.0)


Net cash used in operating activities of discontinued operations

(0.6)



(0.1)


Total adjustments

139.3



94.6


Net cash provided by operating activities

414.4



251.6


Cash flows from investing activities:




Acquisition of businesses, net of cash acquired

(97.7)



(1.1)


Purchases of property and equipment

(212.7)



(166.6)


Additions to capitalized software costs

(10.0)



(4.4)


Other, net

(1.2)



(3.0)


Net cash used in investing activities

(321.6)



(175.1)






Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Continued)

(Unaudited)



Six Months Ended June 30,


2021


2020


(In Millions)

Cash flows from financing activities:




Proceeds from bond issuance



592.5


Principal payments on debt, including pre-payments

(207.3)



(11.0)


Borrowings on revolving credit facility

45.0



330.0


Payments on revolving credit facility



(375.0)


Principal payments under finance lease obligations

(11.8)



(10.9)


Repurchases of common stock, including fees and expenses



(4.9)


Dividends paid on common stock

(56.9)



(56.7)


Purchase of equity interests in consolidated affiliates



(162.3)


Distributions paid to noncontrolling interests of consolidated affiliates

(52.7)



(37.4)


Taxes paid on behalf of employees for shares withheld

(16.4)



(15.7)


Contributions from consolidated affiliates

36.1



16.8


Other, net

0.1



(11.5)


Net cash (used in) provided by financing activities

(263.9)



253.9


(Decrease) increase in cash, cash equivalents, and restricted cash

(171.1)



330.4


Cash, cash equivalents, and restricted cash at beginning of year

310.9



159.6


Cash, cash equivalents, and restricted cash at end of year

$

139.8



$

490.0






Reconciliation of Cash, Cash Equivalents, and Restricted Cash




Cash and cash equivalents at beginning of period

$

224.0



$

94.8


Restricted cash at beginning of period

65.4



57.4


Restricted cash included in other long-term assets at beginning of period

21.5



7.4


Cash, cash equivalents, and restricted cash at beginning of period

$

310.9



$

159.6






Cash and cash equivalents at end of period

$

73.2



$

419.0


Restricted cash at end of period

65.0



56.4


Restricted cash included in other long-term assets at end of period

1.6



14.6


Cash, cash equivalents, and restricted cash at end of period

$

139.8



$

490.0


Encompass Health Corporation and Subsidiaries

Supplemental Information

Earnings Per Share



Three Months Ended
June 30,


Six Months Ended
June 30,


2021


2020


2021


2020


(In Millions, Except Per Share Data)

Adjusted EBITDA

$

278.9



$

162.2



$

529.7



$

390.2


Depreciation and amortization

(63.4)



(60.7)



(125.9)



(119.5)


Interest expense and amortization of debt discounts and fees

(41.8)



(45.8)



(84.6)



(89.0)


Stock-based compensation expense

(12.0)



(9.9)



(14.8)



(17.0)


Loss on disposal or impairment of assets

(2.9)



(3.0)



(2.8)



(3.1)



158.8



42.8



301.6



161.6


Certain items non-indicative of ongoing operating performance:








Loss on early extinguishment of debt

(1.0)





(1.0)




Costs associated with the strategic alternatives review

(4.1)





(5.0)




Costs associated with the Frontier acquisition

(1.3)





(1.3)




Gain on consolidation of former equity method location







2.2


Change in fair market value of equity securities

0.7



2.4



0.6



(0.1)


Government, class action, and related settlements







(2.8)


Payroll taxes on SARs exercise







(1.5)


Pre-tax income

153.1



45.2



294.9



159.4


Income tax expense

(39.5)



(11.8)



(74.0)



(38.9)


Income from continuing operations (1)

$

113.6



$

33.4



$

220.9



$

120.5










Basic shares

99.0



98.7



99.0



98.5


Diluted shares

100.2



99.9



100.2



99.6










Basic earnings per share (1)

$

1.14



$

0.34



$

2.22



$

1.22


Diluted earnings per share (1)

$

1.13



$

0.34



$

2.20



$

1.21




(1)

Income from continuing operations attributable to Encompass Health

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share



Q2


6 Months


2021


2020


2021


2020









Earnings per share, as reported

$

1.13



$

0.34



$

2.20



$

1.21


Adjustments, net of tax:








Government, class action, and related settlements







0.02


Costs associated with the strategic alternatives review

0.03





0.04




Costs associated with the Frontier acquisition

0.01





0.01




Income tax adjustments





(0.03)



(0.05)


Loss on early extinguishment of debt

0.01





0.01




Change in fair market value of equity securities



(0.02)






Gain on consolidation of former equity method location







(0.02)


Payroll taxes on SARs exercise







0.01


Adjusted earnings per share*

$

1.17



$

0.31



$

2.22



$

1.18




*

Adjusted EPS may not sum due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share



For the Three Months Ended June 30, 2021




Adjustments




As
Reported


Loss on
Early
Exting. of
Debt


Income Tax
Adjustments


Costs
Associated
with the
Strategic
Alternatives
Review


Costs
Associated
with the
Frontier
Acquisition


Change in
Fair
Market
Value of
Equity
Securities


As
Adjusted


(In Millions, Except Per Share Amounts)

Adjusted EBITDA*

$

278.9



$



$



$



$



$



$

278.9


Depreciation and amortization

(63.4)













(63.4)


Interest expense and amortization of debt discounts and fees

(41.8)













(41.8)


Stock-based compensation

(12.0)













(12.0)


Loss on disposal or impairments of assets

(2.9)













(2.9)


Loss on early extinguishment of debt

(1.0)



1.0












Costs associated with the strategic alternatives review

(4.1)







4.1








Costs associated with the Frontier acquisition

(1.3)









1.3






Change in fair market value of equity securities

0.7











(0.7)




Income from continuing operations before income tax expense

153.1



1.0





4.1



1.3



(0.7)



158.8


Provision for income tax expense

(39.5)



(0.3)



(0.1)



(1.1)



(0.3)



0.2



(41.1)


Income from continuing operations attributable to Encompass Health

$

113.6



$

0.7



$

(0.1)



$

3.0



$

1.0



$

(0.5)



$

117.7


Diluted earnings per share from continuing operations**

$

1.13



$

0.01



$



$

0.03



$

0.01



$



$

1.17


Diluted shares used in calculation

100.2
















*

See reconciliation of net income to Adjusted EBITDA

**

Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share



For the Three Months Ended June 30, 2020




Adjustments




As Reported


Income Tax
Adjustments


Change in Fair
Market Value of
Equity
Securities


As Adjusted


(In Millions, Except Per Share Amounts)

Adjusted EBITDA*

$

162.2



$



$



$

162.2


Depreciation and amortization

(60.7)







(60.7)


Interest expense and amortization of debt discounts and fees

(45.8)







(45.8)


Stock-based compensation

(9.9)







(9.9)


Loss on disposal or impairments of assets

(3.0)







(3.0)


Change in fair market value of equity securities

2.4





(2.4)




Income from continuing operations before income tax expense

45.2





(2.4)



42.8


Provision for income tax expense

(11.8)



(0.4)



0.6



(11.6)


Income from continuing operations attributable to Encompass Health

$

33.4



$

(0.4)



$

(1.8)



$

31.2


Diluted earnings per share from continuing operations**

$

0.34



$



$

(0.02)



$

0.31


Diluted shares used in calculation

99.9










*

See reconciliation of net income to Adjusted EBITDA

**

Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share



For the Six Months Ended June 30, 2021




Adjustments



As
Reported


Loss on
Early
Exting.
of Debt


Income Tax
Adjustments


Costs Associated
with the
Strategic
Alternatives
Review


Costs
Associated
with the
Frontier
Acquisition


Change in
Fair Market
Value of
Equity
Securities


As
Adjusted


(In Millions, Except Per Share Amounts)

Adjusted EBITDA*

$

529.7



$



$



$



$



$



$

529.7


Depreciation and amortization

(125.9)













(125.9)


Loss on early extinguishment of debt

(1.0)



1.0












Interest expense and amortization of debt discounts and fees

(84.6)













(84.6)


Stock-based compensation

(14.8)













(14.8)


Loss on disposal or impairment of assets

(2.8)













(2.8)


Costs associated with the strategic alternatives review

(5.0)







5.0








Costs associated with the Frontier acquisition

(1.3)









1.3






Change in fair market value of equity securities

0.6











(0.6)




Income from continuing operations before income tax expense

294.9



1.0





5.0



1.3



(0.6)



301.6


Provision for income tax expense

(74.0)



(0.3)



(3.4)



(1.3)



(0.3)



0.2



(79.1)


Income from continuing operations attributable to Encompass Health

$

220.9



$

0.7



$

(3.4)



$

3.7



$

1.0



$

(0.4)



$

222.5


Diluted earnings per share from continuing operations**

$

2.20



$

0.01



$

(0.03)



$

0.04



$

0.01



$



$

2.22


Diluted shares used in calculation

100.2
















*

See reconciliation of net income to Adjusted EBITDA

**

Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share



For the Six Months Ended June 30, 2020




Adjustments




As
Reported


Gov't, Class
Action, &
Related
Settlements


Income Tax
Adjustments


Change in
Fair
Market
Value of
Equity
Securities


Gain on
Consolidation
of Former
Equity
Method
Location


Payroll
Taxes on
SARs
Exercise


As
Adjusted


(In Millions, Except Per Share Amounts)

Adjusted EBITDA*

$

390.2



$



$



$



$



$



$

390.2


Depreciation and amortization

(119.5)













(119.5)


Government, class action, and related settlements

(2.8)



2.8












Interest expense and amortization of debt discounts and fees

(89.0)













(89.0)


Stock-based compensation

(17.0)













(17.0)


Loss on disposal or impairment of assets

(3.1)













(3.1)


Change in fair market value of equity securities

(0.1)







0.1








Gain on consolidation of Treasure Coast

2.2









(2.2)






Payroll taxes on SARs exercise

(1.5)











1.5




Income from continuing operations before income tax expense

159.4



2.8





0.1



(2.2)



1.5



161.6


Provision for income tax expense

(38.9)



(0.7)



(4.7)





0.6



(0.4)



(44.1)


Income from continuing operations attributable to Encompass Health

$

120.5



$

2.1



$

(4.7)



$

0.1



$

(1.6)



$

1.1



$

117.5


Diluted earnings per share from continuing operations**

$

1.21



$

0.02



$

(0.05)



$



$

(0.02)



$

0.01



$

1.18


Diluted shares used in calculation

99.6
















*

See reconciliation of net income to Adjusted EBITDA

**

Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA



Three Months Ended
June 30,


Six Months Ended
June 30,


2021


2020


2021


2020


(In Millions)

Net income

$

142.0



$

48.3



$

274.8



$

157.0


Loss (income) from discontinued operations, net of tax, attributable to Encompass Health

0.3



(0.1)



0.3




Net income attributable to noncontrolling interests

(28.7)



(14.8)



(54.2)



(36.5)


Government, class action, and related settlements







2.8


Provision for income tax expense

39.5



11.8



74.0



38.9


Interest expense and amortization of debt discounts and fees

41.8



45.8



84.6



89.0


Depreciation and amortization

63.4



60.7



125.9



119.5


Loss on early extinguishment of debt

1.0





1.0




Loss on disposal or impairment of assets

2.9



3.0



2.8



3.1


Stock-based compensation expense

12.0



9.9



14.8



17.0


Costs associated with the strategic alternatives review

4.1





5.0




Costs associated with the Frontier acquisition

1.3





1.3




Gain on consolidation of former equity method location







(2.2)


Change in fair market value of equity securities

(0.7)



(2.4)



(0.6)



0.1


Payroll taxes on SARs exercise







1.5


Adjusted EBITDA

$

278.9



$

162.2



$

529.7



$

390.2



Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations

Before Income Tax Expense



Three Months Ended

June 30,


Six Months Ended

June 30,


Year Ended

December 31,


2021


2020


2021


2020


2020


(In Millions)

Total segment Adjusted EBITDA

$

315.7



$

195.3


$

601.4



$

451.8



$

986.3

General and administrative expenses

(54.2)



(43.0)


(92.8)



(78.6)



(155.5)

Depreciation and amortization

(63.4)



(60.7)


(125.9)



(119.5)



(243.0)

Loss on disposal or impairment of assets

(2.9)



(3.0)


(2.8)



(3.1)



(11.6)

Government, class action, and related settlements






(2.8)



(2.8)

Loss on early extinguishment of debt

(1.0)




(1.0)





(2.3)

Interest expense and amortization of debt discounts and fees

(41.8)



(45.8)


(84.6)



(89.0)



(184.2)

Net income attributable to noncontrolling interests

28.7



14.8


54.2



36.5



84.6

Change in fair market value of equity securities

0.7



2.4


0.6



(0.1)



0.4

Gain on consolidation of former equity method location






2.2



2.2

Payroll taxes on SARs exercise






(1.5)



(1.5)

Income from continuing operations before income tax expense

$

181.8



$

60.0


$

349.1



$

195.9



$

472.6

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA



Three Months Ended
June 30,


Six Months Ended
June 30,


Year Ended
December 31,


2021


2020


2021


2020


2020


(In Millions)

Net cash provided by operating activities

$

255.9



$

222.3



$

414.4



$

251.6



$

704.7


Interest expense and amortization of debt discounts and fees

41.8



45.8



84.6



89.0



184.2


Equity in net income of nonconsolidated affiliates

1.0



0.7



2.0



1.5



3.5


Net income attributable to noncontrolling interests in continuing operations

(28.7)



(14.8)



(54.2)



(36.5)



(84.6)


Amortization of debt-related items

(2.0)



(1.7)



(4.0)



(3.1)



(7.2)


Distributions from nonconsolidated affiliates

(0.8)



(1.0)



(1.8)



(2.0)



(3.8)


Current portion of income tax expense

42.0



22.3



67.8



48.0



51.4


Change in ass